Our Strategic Objectives

Green Rock Capital aims to create a regional impactful ecosystem and generate significant economic benefit for its investors.

Our Vision

To become one of the world's bitechnology and digital health investors of reference.

Our Mission

To invest in and enable a nurturing ecosystem for businesses and start-ups and connect with academia, goverment and industry.

Generate Economic

Return for our investors and benefit the broader ecosystem through high-value jobs creation and promotion of the knowledge economy in the region

Help address

The national priorities and unmet needs in the region by investing and localizing relevant technologies

Create a successful

Built a successful network of strategic partners, fostering innovation and collaboration.

Participate in the enablement

Participate in building of an ecosystem that translate basic research into commercial products.

About Us

At Green Rock Capital Ltd, we are committed to delivering innovative investment solutions tailored to professional clients and market counterparties

We Are Green Rock Capital

Green Rock Capital Ltd is regulated by the DFSA (license number F007419) for advising on Financial Products and Managing a Collective Investment Fund, established in the DIFC under the DIFC Companies Law. This site’s information is intended only for Professional Clients or Market Counterparties as defined by the DFSA and is not for Retail Clients. All content, including factsheets and presentations, is for informational purposes only and does not constitute an offer, solicitation, or personal recommendation. Products and services are subject to relevant terms, conditions, and disclaimers. All our products and services are subject to the relevant terms and conditions and disclaimers governing their use

Read More

What are we solving for?

The Content

Sustained global R&D spending is driving innovation, while AI is revolutionizing drug discovery. Advancements in computational power, especially in genetic sequencing, enable deeper insights. Big tech’s heavy investments are accelerating progress, yet low valuations and fundraising challenges create hurdles for smaller biotech firms.

The Problem

With an aging population increasingly prone to chronic diseases, longevity presents a growing challenge. Strategic unmet needs in water, food, and vaccines highlight the region's low self-sufficiency. The GCC lacks homegrown biotech innovators, and investors struggle to price risk, limiting advancements in the sector. Tempore laborum nesciunt ut veniam, nemo officia ullam repudiandae repellat veritatis unde reiciendis possimus animi autem natus

The Opportunity

Investing in cutting-edge breakthroughs like CGT, CAR-T, and CRISPR offers a chance to reshape healthcare. By opening biotech and digital health sectors to regional investors, there’s an immediate opportunity to acquire premium tech at low valuations. Localizing IP and attracting companies and talent can establish a thriving biotech ecosystem.

Track Record of Excellence

72% Success Rate

The founders have successfully backed and grown biotech companies with a 72% investment success rate.

Strong Returns

Our investments have delivered an average annual return of 22%.

Successful Exits

Over 15 portfolio companies have achieved successful exits under our guidance.

Industry Recognition

Our expertise has been acknowledged in top publications like The Wall Street Journal, Forbes, and BusinessWeek.

Address

Unit 13, Level 6, Gate District Precinet Building 04 Monday-Friday: 9am - 6pm info@greenrock.com

Links

Home About Investment Model Governance Model Key People

Subscribe

© All Rights Reserved By Green Rock Capital